U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H21ClN2O
Molecular Weight 352.857
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PK-11195

SMILES

CCC(C)N(C)C(=O)C1=NC(C2=CC=CC=C2Cl)=C3C=CC=CC3=C1

InChI

InChIKey=RAVIZVQZGXBOQO-UHFFFAOYSA-N
InChI=1S/C21H21ClN2O/c1-4-14(2)24(3)21(25)19-13-15-9-5-6-10-16(15)20(23-19)17-11-7-8-12-18(17)22/h5-14H,4H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C21H21ClN2O
Molecular Weight 352.857
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

PK-11195 was first discovered by Pharmuka Laboratories. It was found to be antagonist of the Translocator Protein (TSPO) with potential for development in a number of conditions including cancer models, cardiac ischemia, seizures, depression, and anxiety. PK-11195 has been studied extensively in vitro and in animal models. In phase I clinical trials no anti-inchemic effects were found after drug administration. A tritium [3H] labeled and a C-11 labeled version of PK-11195 are both used diagnostically as PET imaging compounds.

CNS Activity

Curator's Comment: PK-11195 C-11 is used in PET to visualize brain inflammation in patients with neuronal damage. Activity was shown in mice.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P50637
Gene ID: 12257.0
Gene Symbol: Tspo
Target Organism: Mus musculus (Mouse)
2.4 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
126.9 μg/L
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
211.4 μg/L
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
342 μg/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
432.23 μg × h/L
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1171.8 μg × h/L
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2926.6 μg × h/L
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5872.1 μg × h/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.72 h
10 mg single, intravenous
dose: 10 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.8 h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.9 h
200 mg single, intravenous
dose: 200 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.6 h
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PK-11195 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
PubMed

PubMed

TitleDatePubMed
Improved assays for xenosensor activation based on reverse transfection.
2015-10
Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR).
2015-03-04
TO901317, a potent LXR agonist, is an inverse agonist of CAR.
2013
Synthesis and evaluation of novel carbon-11 labeled oxopurine analogues for positron emission tomography imaging of translocator protein (18 kDa) in peripheral organs.
2011-09-08
Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
2011-08-15
Modulation of constitutive androstane receptor (CAR) and pregnane X receptor (PXR) by 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives, ligands of peripheral benzodiazepine receptor (PBR).
2011-04-25
Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands.
2010-12-05
Decreases in binding capacity of the mitochondrial 18 kda translocator protein accompany oxidative stress and pathological signs in rat liver after DMBA exposure.
2010-10
A consecutive three alanine residue insertion mutant of human CAR: a novel CAR ligand screening system in HepG2 cells.
2010-08
Human dosimetry of carbon-11 labeled N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide extrapolated from whole-body distribution kinetics and radiometabolism in rats.
2010-08
Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo.
2010-01-25
Bacterial ortholog of mammalian translocator protein (TSPO) with virulence regulating activity.
2009-06-30
Synthesis, labeling, and biological evaluation of halogenated 2-quinolinecarboxamides as potential radioligands for the visualization of peripheral benzodiazepine receptors.
2006-06-15
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
2005-09-15
Structure of the Mg-chelatase cofactor GUN4 reveals a novel hand-shaped fold for porphyrin binding.
2005-05
Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1.
2004-11
Involvement of steroids in anti-inflammatory effects of peripheral benzodiazepine receptor ligands.
2004-01-30
Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species.
2003-12-01
Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor.
2003-07
Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria.
2002-07-01
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells.
2001-04
Intrathecally administered flumazenil and PK 11195 precipitate abstinence syndrome in freely moving diazepam dependent rats.
1996-12-11
PK 11195 reduces the brain availability of lindane in rats and the convulsions induced by this neurotoxic agent.
1995
Patents

Sample Use Guides

Mice received an intraperitoneal injection of PK-11195 (30 - 120 mg/kg ) 30 min before inducing convulsions with one of Ro 5-4864, Ro 5- 3663, PTZ or picrotoxin. Results were mixed. PK-11195 significantly reduced the incidence of convulsions caused by Ro 5-4864 but was ineffective at countering seizures brought on by Ro 5-3663 and picrotoxin. Furthermore, PK 11195 had pro-convulsant actions when combined with sub-convulsant doses of strychnine and picrotoxin.
Route of Administration: Other
Human breast cancer cell lines MCF-7 and T47D were cultured and viability and proliferation were determined with a CCK-8 assay. A TSPO selective ligand AC-5216 was added to enhance cellular proliferation and production of allopregnanolone. PK-11195 blocked the effects of AC-5216 with IC50 values of 5.4 nM and 6 nM in MCF-7 and T47D cells respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 23:01:52 GMT 2025
Edited
by admin
on Mon Mar 31 23:01:52 GMT 2025
Record UNII
YNF83VN1RL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RP-52028
Preferred Name English
PK-11195
Common Name English
PK 11195
Common Name English
3-ISOQUINOLINECARBOXAMIDE, 1-(2-CHLOROPHENYL)-N-METHYL-N-(1-METHYLPROPYL)-
Systematic Name English
N-METHYL-N-(1-METHYLPROPYL)-1-(2-CHLOROPHENYL)ISOQUINOLINE-3-CARBOXAMIDE
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID7041097
Created by admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
PRIMARY
PUBCHEM
1345
Created by admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
PRIMARY
WIKIPEDIA
PK-11195
Created by admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
PRIMARY
FDA UNII
YNF83VN1RL
Created by admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
PRIMARY
CAS
85532-75-8
Created by admin on Mon Mar 31 23:01:52 GMT 2025 , Edited by admin on Mon Mar 31 23:01:52 GMT 2025
PRIMARY
Related Record Type Details
LABELED -> NON-LABELED
LABELED -> NON-LABELED
Related Record Type Details
ACTIVE MOIETY